Addiction (Abingdon, England)
March 30, 2026
Sarah J Catchlove, Katrin Oliver, Michael Savic et al.
Australia recently down-scheduled and authorised psychedelic-assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness. While service leaders and clinicians are crucial to implementation, little research examines their...
Drugs Education Prevention and Policy
March 22, 2026
Jordan J. Negrine, Stephen Bright, Monica J Barratt et al.
Background Following Australia’s landmark 2023 decision to approve psilocybin and MDMA for clinical use, psychedelic-assisted therapy (PAT) is beginning to emerge within regulated mental health settings. This study investigates psychologists’ views on the relevance of psychedelic therapists’ lived-living experience (LLE) with psychedelics. While discussion around LLE is growing, little is known...
Journal of Traumatic Stress
March 12, 2026
Leslie A. Morland, Barbara O Rothbaum, Lauren M. Sippel et al.
2 citations
There is growing interest in novel approaches to treating posttraumatic stress disorder (PTSD), including the use of psychedelic substances combined with psychotherapy, often referred to as psychedelic-assisted therapy, to better meet the needs of patients who do not prefer or respond to traditional evidence-based treatments. Among these treatments, 3,4-methylenedioxymethamphetamine...
Br J Psychiatry
March 6, 2026
Tor-Morten Kvam, Ivar Walderhaug Goksøyr, Justyna Rog et al.
MDMA-assisted psychotherapy in major depression: critical considerations for clinical translation: commentary, Kvam et al.
Journal of Psychedelic Studies
March 1, 2026
Yvan Beaussant, Candace Oglesby, Kim Roddy et al.
Abstract Background and aims Psychedelic-assisted therapies (PAT) have emerged as promising treatments for mental health conditions such as depression, anxiety, and trauma-related disorders. However, the underrepresentation of Black, Indigenous, and People of Color (BIPOC) in PAT research and clinical practice limits equitable access and the generalizability of outcomes. This study explored the...
Psychedelic medicine (New Rochelle, N.Y.)
March 1, 2026
Veronica Szpak, Samuel Maddams, Amanda Kim et al.
New treatment options are needed to improve outcomes for patients with both opioid use disorder (OUD) and injection-related infections. Psychedelic-assisted therapy (PAT) has been suggested as a potential treatment for substance use disorders (SUD). To address this need, a qualitative study was conducted to understand the attitudes toward PAT from individuals with OUD who have survived...
Journal of Palliative Medicine
March 1, 2026
Robert K Horowitz, William E Rosa, Ali John Zarrabi et al.
Psychospiritual distress (PSD) causes profound suffering in people with serious illness, yet treatment options are few and evidence of their efficacy is modest. Although high-level evidence is limited, decades of preliminary research suggest that psychedelic-assisted psychotherapy (PAP), including ketamine-assisted psychotherapy (KAP), may alleviate the anxiety, depression, and existential...
Therapeutic Advances in Psychopharmacology
March 1, 2026
Guillaume Thuery, Frank Crossen, Daniel Mc Loone et al.
1 citation
Approximately 15% of pregnant women experience postpartum depression (PPD). Even with currently available antidepressant treatments, many women will continue to be impaired by symptoms. Psychedelic therapy offers a promising transdiagnostic therapeutic strategy for several mental health disorders, and early results from current trials suggest that serotonergic psychedelics may represent a...
Therapeutic Advances in Psychopharmacology
March 1, 2026
Ana Deutsch, Luis E. Contreras, Sarah Kratina et al.
Background: Psychedelic therapies are gaining attention as tools to alleviate anxiety and depression across various clinical populations. However, the mechanisms behind psychedelics' therapeutic efficacy and the potential differences in how patients with certain diagnoses experience their subjective effects remain unknown. One commonly suggested mediator of positive outcomes across psychedelics...